Enlivex Therapeutics Releases Interim Data Readout From Phase I/II AllocetraTM Trial Showing; Three-Month Readout Showed Avg. Pain Reduciotn Of 64%, 33% Of Patients Reported Pain Resolution, 89% Of Patients Did Not Proceed With Knee Replacement Surgery
Portfolio Pulse from Benzinga Newsdesk
Enlivex Therapeutics released interim data from its Phase I/II AllocetraTM trial, showing a 64% average pain reduction, 33% of patients reported pain resolution, and 89% did not proceed with knee replacement surgery.
June 17, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Enlivex Therapeutics' interim data from its Phase I/II AllocetraTM trial shows significant positive results, including a 64% average pain reduction, 33% pain resolution, and 89% of patients avoiding knee replacement surgery.
The positive interim data from the AllocetraTM trial is likely to boost investor confidence in Enlivex Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100